Package Leaflet: Information for the User
Volibris 2.5mg film-coated tablets
Volibris 5mg film-coated tablets
Volibris 10mg film-coated tablets
ambrisentan
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack
Volibris contains the active substance ambrisentan. It belongs to a group of medicines called other antihypertensives (used to treat high blood pressure).
It is indicated for the treatment of pulmonary arterial hypertension (PAH) in adults, adolescents, and children aged 8 years and older. PAH is a condition where the blood pressure in the blood vessels (the pulmonary arteries) that carry blood from the heart to the lungs is too high. In people with PAH, these blood vessels become narrower, so the heart has to work harder to pump blood to the lungs. This makes people feel tired, dizzy, and have difficulty breathing.
Volibris widens the pulmonary arteries, making it easier for the heart to pump blood through them. This reduces blood pressure and alleviates symptoms.
Volibris may also be used in combination with other medicines used to treat PAH.
Do not take Volibris
Warnings and precautions
Talk to your doctor before starting to take this medicine:
→ Your doctor will decideif Volibris is suitable for you.
You will need to have regular blood testsBefore you start taking Volibris, and periodically while you are taking it, your doctor will perform blood tests to check:
→It is important that you have these blood tests regularly while taking Volibris.
The signs that your liver may not be working properly include:
If you notice any of these:
→ Tell your doctor immediately.
Children
Do not give this medicine to children under 8 years old, as the safety and efficacy in this age group are unknown.
Taking Volibris with other medicines
Tell your doctor or pharmacistif you are taking, have recently taken, or might take any other medicines.
If you start taking cyclosporin A(a medicine used after a transplant or to treat psoriasis), your doctor may need to adjust your dose of Volibris.
If you are taking rifampicin(an antibiotic used to treat serious infections), your doctor will monitor you when you start taking Volibris.
If you are taking other medicines for PAH (iloprost, epoprostenol, sildenafil), your doctor may need to monitor you.
→ Tell your doctor or pharmacistif you are taking this medicine.
Pregnancy
Volibris may harm the unborn baby conceived before, during, or shortly after treatment.
→ If you may become pregnant, use a reliable method of birth controlwhile taking Volibris. Consult your doctor about this.
→ Do not take Volibris if you are pregnant or planning to become pregnant.
→ If you become pregnant or think you may be pregnantwhile taking Volibris, consult your doctor immediately.
If you are a woman of childbearing age, your doctor will ask you to have a pregnancy testbefore starting to take Volibris and periodically while taking this medicine.
Breast-feeding
It is not known if the active ingredient of Volibris can pass into breast milk.
→ Do not breast-feed while taking Volibris.Consult your doctor about this.
Fertility
If you are a man taking Volibris, this medicine may reduce your sperm count. Talk to your doctor if you have any questions or concerns about this.
Driving and using machines
Volibris may cause side effects such as low blood pressure, dizziness, fatigue (see section 4) that may affect your ability to drive and use machines. The symptoms of your disease may also reduce your ability to drive or use machines
→ Do not drive or use machines if you do not feel well.
Volibris contains lactose
The tablets of Volibris contain small amounts of a sugar called lactose. If your doctor has told you that you have an intolerance to some sugars:
→ Consult your doctorbefore taking this medicine.
Volibris contains soybean lecithin
Do not use this medicine if you are allergic to soy (see section 2 "Do not take Volibris").
The 5 mg and 10 mg tablets of Volibris contain a colorant calledred allura AC (E129)
This may cause allergic reactions (see section 4).
Volibris contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow exactly the instructions for taking this medicine given by your doctoror pharmacist.If you are unsure, consult your doctor or pharmacist again.
How much Volibris to take
AdultsThe usual dose is one 5 mg tablet, once a day. Your doctor may decide to increase your dose to 10 mg, once a day.
If you are taking cyclosporin A, do not take more than one 5 mg tablet of Volibris, once a day.
Adolescents and children from 8 years to less than 18 years of age
Usual starting dose of Volibris | |
Weight of 35 kg or more | One 5mgtablet, once a day |
Weight of at least 20 kg and less than 35 kg | One 2.5mgtablet, once a day |
Your doctor may decide to increase your dose. It is important that children attend their regular medical appointments, as their dose needs to be adjusted as they grow or gain weight.
If taken in combination with cyclosporin A, the dose of Volibris should be limited to 2.5 mg once a day in adolescents and children who weigh less than 50 kg or to 5 mg once a day if they weigh 50 kg or more.
How to take VolibrisIt is best to take the tablet at the same time every day. Swallow the tablet whole, with a glass of water; do not divide, crush, or chew the tablet. You can take Volibris with or without food.
How to remove the tablet from the blister pack (only for 5 mg and 10 mg tablets)
These tablets come in a special packaging to prevent children from accessing them.
The 2.5 mg tablets of Volibris are supplied in a bottle, not in a blister pack.
If you take more Volibris than you should
If you take too many tablets, you may be more likely to have side effects, such as headache, flushing, dizziness, nausea (feeling sick), or low blood pressure, which can cause a mild feeling of dizziness:
→ Ask your doctor or pharmacist for adviceif you take more tablets than prescribed.
If you forget to take Volibris
If you forget to take a dose of Volibris, take it as soon as you remember and then continue as before.
→ Do not take a double dose to make up for forgotten doses.
If you stop taking Volibris
Volibris is a treatment that you will need to continue taking to control your PAH.
→Do not stop taking Volibris unless your doctor tells you to.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Tell your doctorif you get any of these:
Allergic reactions
This is a common side effect that may affect up to 1 in 10people. You may notice:
Swelling (edema), especially of the ankles and feet
This is a very common side effect that may affect more than 1 in 10people.
Heart failure
This is because the heart is not pumping enough blood. This is a common side effect that may affect up to 1 in 10people. The symptoms include:
Low red blood cell count (anemia)
This is a very common side effect that may affect more than 1 in 10people. Sometimes this requires a blood transfusion. The symptoms include:
Low blood pressure (hypotension)
This is a common side effect that may affect up to 1 in 10people. The symptoms include:
→Tell your doctor immediatelyif you (or your child) experience these effects or if they occur suddenly after taking Volibris.
It is important to have regular blood tests, to check if you have anemia and that your liver is working properly. Also, make sure you have read the information in section 2about "the need for regular blood tests" and "signs that your liver may not be working properly".
Other side effects
Very common(may affect more than 1 in 10people)
In combination with tadalafil (another medicine for PAH)
In addition to the above:
Common(may affect up to 1 in 10people)
In combination with tadalafil
In addition to the above, except for abnormal results in blood tests for liver function:
Uncommon(may affect up to 1 in 100people)
In combination with tadalafil
Side effects in children and adolescents
These are expected to be similar to those listed above for adults.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the pack after EXP.
The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Volibris Composition
The active ingredient is ambrisentan.
Each film-coated tablet contains 2.5 mg, 5 mg, or 10 mg of ambrisentan.
For the 2.5mg tablets:
The other ingredients are: lactose monohydrate, microcrystalline cellulose, sodium croscarmellose, magnesium stearate, polyvinyl alcohol, talc, titanium dioxide (E171), macrogol, and soy lecithin (E322).
For the 5mg and 10mg tablets:
The other ingredients are: lactose monohydrate, microcrystalline cellulose, sodium croscarmellose, magnesium stearate, polyvinyl alcohol, talc, titanium dioxide (E171), macrogol, soy lecithin (E322), and red allura AC aluminum lake (E129).
Product Appearance and Package Contents
Volibris 2.5 mg film-coated tablets (tablet) are white, round, 7 mm, convex, engraved with “GS” on one side and “K11” on the other side.
Volibris 5 mg film-coated tablets (tablet) are pale pink, square, 6.6 mm, convex, engraved with "GS" on one side and "K2C" on the other side.
Volibris 10 mg film-coated tablets (tablet) are dark pink, oval, 9.8 mm x 4.9 mm, convex, engraved with "GS" on one side and "KE3" on the other side.
Volibris is supplied as 2.5 mg film-coated tablets in a bottle. Each bottle contains 30 tablets.
Volibris is supplied as 5 mg and 10 mg film-coated tablets in single-dose blisters, in packs of 10 × 1 or 30 × 1 tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder
GlaxoSmithKline (Ireland) Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
Manufacturer
GlaxoSmithKline Trading Services Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Belgium GlaxoSmithKline Pharmaceuticals s.a./n.v. Tel: + 32 (0) 10 85 52 00 | Lithuania GlaxoSmithKline (Ireland) Limited Tel: + 370 80000334 |
Luxembourg GlaxoSmithKline Pharmaceuticals s.a./n.v. Belgium Tel: + 32 (0) 10 85 52 00 | |
Czech Republic GlaxoSmithKline s.r.o. Tel: + 420 222 001 111 cz.info@gsk.com | Hungary GlaxoSmithKline (Ireland) Limited Tel.: + 36 80088309 |
Denmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-info@gsk.com | Malta GlaxoSmithKline (Malta) Limited Tel: + 356 80065004 |
Germany GlaxoSmithKline GmbH & Co. KG Tel.: + 49 (0)89 36044 8701 produkt.info@gsk.com | Netherlands GlaxoSmithKline BV Tel: + 31 (0) 33 2081100 |
Estonia GlaxoSmithKline (Ireland) Limited Tel: + 372 8002640 | Norway GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Greece GlaxoSmithKline Μονοπρ?σωπη A.E.B.E. Τηλ: + 30 210 68 82 100 | Austria GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 at.info@gsk.com |
Spain GlaxoSmithKline, S.A. Tel: + 34 900 202 700 es-ci@gsk.com | Poland GSK Services Sp. z o.o. Tel.: + 48 (0)22 576 9000 |
France Laboratoire GlaxoSmithKline Tél: + 33 (0)1 39 17 84 44 diam@gsk.com | Portugal GlaxoSmithKline – Produtos Farmacêuticos, Lda. Tel: + 351 21 412 95 00 FI.PT@gsk.com |
Croatia GlaxoSmithKline (Ireland) Limited Tel: + 385 800787089 | Romania GlaxoSmithKline (Ireland) Limited. Tel: + 40 800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenia GlaxoSmithKline (Ireland) Limited Tel: + 386 80688869 |
Iceland Vistor hf. Sími: + 354 535 7000 | Slovakia GlaxoSmithKline (Ireland) Limited Tel: + 421 800500589 |
Italy GlaxoSmithKline S.p.A. Tel: + 39 (0)45 7741 111 | Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 |
Cyprus GlaxoSmithKline (Ireland) Limited Τηλ: + 357 80070017 | Sweden GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com |
Latvia GlaxoSmithKline (Ireland) Limited Tel: + 371 80205045 | United Kingdom (Northern Ireland) GlaxoSmithKline (Ireland) Limited Tel: + 44 (0)800 221441 customercontactuk@gsk.com |
Date of the Last Revision of thisLeaflet:
Other Sources of Information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/. It also provides links to other websites on rare diseases and orphan medicines.